Stock Research
In-depth breakdowns of real companies — the thesis, the numbers behind it, and what would change our mind.
Institutional format, plainly written.
Every note follows the same shape — a crisp thesis, the setup across fundamentals and technicals, and a short list of what to watch next. No hedged fence-sitting, no jargon walls.
Oracle Corp.
A $638B backlog reprices Oracle from legacy database to AI-infrastructure compounder — but only if OCI capacity converts to cash on schedule.
OCI revenue growth, RPO conversion, and free-cash-flow trajectory through the next two prints.
The Coca-Cola Company
Pricing power and margin expansion inside a fortress balance sheet — a defensive compounder trading close to fair value with ~$11B of optionality.
Organic revenue mix, operating margin trend, and capital-return cadence into year-end.
Deep-dives on the names that matter.
Weekly stock research like these notes — fundamentals first, technicals for timing, institutional positioning for confirmation. $30/mo.
Research and education, not financial advice.